biotechnology

Wendy Lam of Oppenheimer maintained an Outperform rating on shares of Gilead Sciences, Inc. (NASDAQ: GILD) and Perform rating on shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Lam noted that Gilead's two core franchises offer a "durable foundation" of substantial...

Biotech analysts at Piper Jaffray stated in a note on Wednesday that "we are buyers on weakness" of select biotech names that boast strong enough balance sheets to "make it through" upcoming value-driving events. The analysts, led by Edward Tenthoff, singled out Vertex Pharmaceuticals Incorporated...

As the broad market charges to new all-time highs, not all stocks and sectors are participating. Two sectors that are going in the exact opposite directions of the market are issues in the healthcare sector and biotech sector. Free-Falling Now The charts of the iShares NASDAQ Biotechnology...

The market this year has been characterized by leadership in defensive sectors such as utilities that have been boosted by falling interest rates and conservatism in the late stages of this bull market. While the momentum in utilities has continued to prosper, a new sector has taken over the top...

We’re waist-deep into the earnings season, and many companies have already filed. The U.S. biotech firm Celgene Corp (NASDAQ: CELG) has filed as well, and its reported earnings beat Wall Street’s expectations. Here are some takeaways from the report. Earnings Overview Revenues...

Short interest can be a very telling component of investor and trader sentiment toward a stock. High or rising short interest typically means that investors and traders believe a stock is going to drop or continue a current decline further. However, high short interest can also be viewed as a...

Earnings season is in full effect with some of the big hitters already hitting the tape. This last week has given us results from the likes of Microsoft (NASDAQ: MSFT), Google (NASDAQ: GOOGL) and Apple (NASDQ: AAPL). On Wednesday morning one of biotechs big hitters, Biogen Idec (NASDAQ: BIIB...

The Nasdaq Composite got hammered Tuesday. The Russell was also slammed pretty hard. The Russell, in particular, broke a key trendline of support, which implies more selling to come. And if you’ve been in the market this year then Tuesday's price action reminds you of March and April...

Merck (NYSE: MRK) paid a 230 percent premium for Hepatitis C-focused Idenix Pharmaceuticals (NASDAQ: IDIX). News of the massive acquisition, earlier this month, sent shares of other Hep C companies, Enanta (NASDAQ: ENTA) and Achillion (NASDAQ: ACHN) higher. In an exclusive interview with...

It seems as if mergers and acquisitions in the healthcare sector has become commonplace, with a lot of biotech companies being main targets. Not a week goes by without multiple discussions about the battle between Valeant Pharmaceuticals (NYSE: VRX) and Allergan(NYSE: AGN). Last week brought...